Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data-Reference-Cited by-同舟云学术

Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data

Published:2014-04 Issue:4 Volume:65 Page:713-720
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Ferté Charles,Koscielny Serge,Albiges Laurence,Rocher Laurence,Soria Jean-Charles,Iacovelli Roberto,Loriot Yohann,Fizazi Karim,Escudier Bernard

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000

2. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009

3. A time to keep and a time to cast away categories of tumor response;Maitland;J Clin Oncol,2011

4. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer;Crabb;J Clin Oncol,2009

5. We should desist using RECIST, at least in GIST;Benjamin;J Clin Oncol,2007

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors;Clinical and Translational Oncology;2024-09-03

2. Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma;Expert Review of Precision Medicine and Drug Development;2024-03-18

3. Hyperprogression after anti-programmed death-1 therapy in a patient with urothelial bladder carcinoma: A case report;World Journal of Clinical Cases;2023-10-06

4. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas;British Journal of Cancer;2023-05-19

5. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time;Journal of Neuroendocrinology;2023-04